microbiome-therapeutics Videos
3 videos found
Destiny Pharma's key consultant and member of the Scientific Advisory Board Professor Dale Gerding provides an update on microbiome therapeutic NTCD-M3 for recurrent C. difficile infections. The NTCD-M3 programme targets the prevention of the recurrence of clostridium difficile infection and has been developed through the world leading research of Professor Dale ...
Mar. 8, 2022
Hear why Notitia, a groundbreaking microbiome bio-therapeutic company, made the decision to headquarter in Middlesex County, New ...
May. 26, 2022